Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2018

View Archived Issues

Discovery and characterization of novel spirocyclic sigma receptor ligands

miR-335 delivery by extracellular vesicles restores tumor suppressor activity in breast cancer model

Phase II data for ruxolitinib in PTCL and CTCL enriched for JAK/STAT pathway alterations

Lilly initiates phase I study of LY-3454738 for atopic dermatitis

Anergis completes proof-of-concept study of second-generation COP allergy vaccines

XEN-901 shows promise in preclinical and first-in-human studies

Synthetic astaxanthin derivative shows promise in the treatment of amyotrophic lateral sclerosis

Takeda presents first-in-human data for TAK-653

Eli Lilly presents phase II data from nextMONARCH 1 study

Novel class of antibacterial compounds targeting the LPS transport system of Gram-negative bacteria

CRISPR activation uses scissors as squeezers

Axovant licenses gene therapies for GM1 and GM2 gangliosidosis from University of Massachusetts

Vaximm initiates phase I/II study of VXM-01 plus avelumab for the treatment of glioblastoma

Taiho Pharmaceutical divulges KDM1A inhibitors

Gut bacteria eat, make neurotransmitter

Oxford University Innovation presents bacterial beta-lactamase inhibitors

Pfizer initiates phase III program for its 20-valent pneumococcal conjugate vaccine

Suzhou Autopharm Biopharmaceutical synthesizes MAP1LC3B inhibitors

Topadur Pharma discloses PDE5A inhibitors

FDA approves Nplate for pediatric patients with immune thrombocytopenia

Trastuzumab biosimilar Herzuma approved by FDA

Janssen Pharmaceuticals and collaborator identify new antivirals for dengue

Vedanta initiates phase II study of VE-303 for recurrent C. difficile infection

FDA clears IND application for BBT-877 for IPF

Valneva begins phase II with VLA-15 for Lyme disease

DSMB recommends continuation of phase III RESOLVE-IT study of elafibranor in NASH

C4X Discovery and Horizon Discovery establish target discovery partnership

FDA approves Motegrity for adults with chronic idiopathic constipation

Concert initiates phase I program with CTP-692 for adjunctive treatment of schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...